Rigel Pharmaceuticals (RIGL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, t ...

Key Takeaways Iovance's Amtagvi sales jumped 183% in the first nine months of 2025, driving growth.IOVA cut its 2025 revenue guidance and withdrew its EU filing for Amtagvi, hurting shares.Rigel's 2025 sales rose 60% to $232M, led by Tavalisse, with 2026 growth projected.Both Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the successful commercialization of their marketed products.While Iovance is a cancer biotech concentrated on developing immunotherapies ...

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update [Accessibility Statement] Skip NavigationSOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. ...

Key Takeaways Rigel Pharmaceuticals expects 2025 sales to rise 60% to $232M, topping prior guidance.Tavalisse drove $158.9M in 2025 sales, up 52%, while Gavreto and Rezlidhia added momentum.RIGL guides 2026 product sales of $255-$265M but faces competition from Sanofi and Eli Lilly drugs.Rigel Pharmaceuticals (RIGL) had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven p ...

Core Insights - Rigel Pharmaceuticals (RIGL) shares have increased by 59% over the past year, significantly outperforming the industry growth of 2% [1][8] - The company's financial performance is primarily driven by its product Tavalisse, which treats adults with low platelet counts due to chronic immune thrombocytopenia (ITP) [4][6] Financial Performance - Preliminary figures indicate that Rigel expects total revenues of $69.4 million for Q4 2025, representing a 21% year-over-year growth [5] - Tavalisse generated $45.6 million in Q4 sales, reflecting a 47% year-over-year increase and accounting for approximately two-thirds of total revenues [6] - Full-year 2025 product sales are projected to rise by 60% year-over-year to $232 million, exceeding previous guidance [9] - For 2026, Rigel anticipates net product sales of $255–$265 million and expects to achieve positive net income [10] Product Portfolio and Pipeline - Rigel's oncology assets, including Gavreto and Rezlidhia, contributed $10.2 million and $9.6 million in quarterly sales, respectively, diversifying the revenue base [7] - The company is advancing its pipeline with a lead candidate, R289, currently in a phase Ib study for lower-risk myelodysplastic syndrome (MDS) [11] - Rigel is exploring label expansion for Rezlidhia in collaboration with major cancer research institutions [12] - A partnership with Eli Lilly for the development of ocadusertib is also in place, with potential milestone payments and royalties [13] Competitive Landscape - Competition is intensifying, particularly with the FDA approval of Sanofi's Wayrilz for a similar indication in ITP, which could threaten Tavalisse's market position [14] - Gavreto faces competition from Eli Lilly's Retevmo in the RET fusion-positive non-small cell lung cancer (NSCLC) market [15] Valuation and Analyst Outlook - Rigel's stock is trading at a slight premium with a price/sales (P/S) ratio of 2.33 compared to the industry average of 2.28 [16] - Recent estimates for Rigel's 2025 and 2026 EPS have increased, indicating a positive analyst outlook [18] - Despite competitive risks, the company's financial guidance for 2026 reflects confidence in sustaining growth and profitability [19]

Core Insights - Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, bringing over 40 years of experience in the biotechnology and pharmaceutical industries [1][2]. Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer [3]. - The company was founded in 1996 and is based in South San Francisco, California [3]. Leadership Appointment - Michael P. Miller's appointment is expected to enhance Rigel's strategic plan, particularly in growing its current portfolio and exploring in-licensing opportunities [2]. - Miller has held significant roles in various companies, including Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals and Senior Vice President at Vivus [2]. Strategic Vision - Miller expressed enthusiasm about joining Rigel, highlighting the company's evolution into a profitable entity with a strong commercial engine that supports a promising development pipeline [3]. - The focus will be on serving more patients with hematologic disorders and cancer, aligning with Rigel's mission [3].

Core Viewpoint - Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL) are appealing to growth-focused investors due to their focus on rare diseases, which can support strong revenue growth despite small patient populations [2] Company Overview - Amicus is a mid-cap stock, while Rigel is classified as a small biotech [2] - Both companies are developing treatments for rare medical conditions with limited existing therapies [2] Product Highlights - Amicus' lead product, Galafold, is the first oral precision medicine for Fabry disease, generating significant revenue [3][6] - Rigel's lead drug, Tavalisse, is an oral spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia (ITP), also showing strong sales growth [3][9] Acquisition Potential - Amicus is set to be acquired by BioMarin Pharmaceutical for $14.50 per share, totaling $4.8 billion, expected to close in Q2 2026 [5][10] - This acquisition could enhance Amicus' value realization beyond organic sales growth [4] Financial Performance - Galafold generated $371.5 million in sales in the first nine months of 2025, a 12% year-over-year increase, contributing over 80% of Amicus' net product sales [6] - Pombiliti + Opfolda, a new therapy for late-onset Pompe disease, generated $77.5 million in sales, up 61% year-over-year [7] - Rigel's Tavalisse sales reached $113.3 million in the first nine months of 2025, a 54% increase year-over-year [9] Future Outlook - Rigel expects total revenues of $294.3 million for 2025, with net product sales of $232 million [12] - The company anticipates fourth-quarter revenues of $69.8 million, a 21.2% increase year-over-year [13] Competitive Landscape - Rigel faces increasing competition in the ITP market, particularly from Sanofi's Wayrilz, which poses a threat to Tavalisse [15][16] - Amicus' reliance on Galafold makes it vulnerable to regulatory setbacks, while Rigel's dependence on Tavalisse highlights its exposure to competitive risks [8][26] Valuation and Performance - In the past six months, FOLD shares have increased by 133.1%, while RIGL shares have risen by 87.2%, compared to the industry return of 21.7% [21] - Amicus has a higher price-to-sales (P/S) ratio of 7.41 compared to Rigel's 2.53, indicating a more expensive valuation [23] Investment Recommendation - Amicus is viewed as a better investment opportunity due to its acquisition by BioMarin and strong sales performance, while Rigel's strategy is seen as riskier due to its dependence on Tavalisse [24][27]

Group 1 - The article focuses on trading biotech stocks around significant events such as trial results and NDA/BLA approvals, indicating a strategic approach to investment in this sector [1] - The analysis covers companies in industries regulated by the FDA, highlighting the importance of regulatory factors in investment decisions [1] Group 2 - The author discloses no current stock or derivative positions in the companies mentioned, ensuring an unbiased perspective in the analysis [2] - The article emphasizes that past performance does not guarantee future results, which is a critical consideration for investors [3]

Core Insights - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is recognized as one of the best-performing affordable stocks under $40, with preliminary results indicating strong revenue growth for Q4 2025 and an optimistic outlook for 2026 [1] Financial Performance - The preliminary revenue for Q4 2025 is projected to be approximately $69.8 million, an increase from $57.6 million in Q4 2024 [2] - Management anticipates gross product sales for Q4 2025 to reach $84.5 million, driven by TAVALISSE net product sales of $45.6 million, GAVRETO net product sales of $10.2 million, and REZLIDHIA net product sales of $9.6 million [2] - For the full year 2025, Rigel expects to achieve around $294.3 million in revenue, up from $179.3 million in 2024, with a projected total revenue for 2026 in the range of $275 million to $290 million [3] Market Sentiment - Following the preliminary results, Wall Street shows a bullish sentiment towards Rigel Pharmaceuticals, with Joseph Pantginis from H.C. Wainwright reiterating a Buy rating and setting a price target of $57 [3] Company Overview - Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted, novel drugs in oncology, immunology, and immune oncology, with a product portfolio that includes Tavalisse, Fostamatinib, and R835 [4]

Core Viewpoint - Rigel Pharmaceuticals is presenting its strategic plan aimed at growth and development in the healthcare sector, focusing on expanding its commercial business and product pipeline while maintaining financial discipline [4]. Group 1: Strategic Objectives - The company has outlined four strategic objectives: grow the commercial business, in-license and add products to the commercial portfolio, advance the product pipeline in the clinic, and maintain financial discipline [4]. - These strategic objectives are interdependent and have been crucial in the company's development over the past five years [4]. Group 2: Historical Context - Five years ago, Rigel was primarily a one-product company with TAVALISSE for adult chronic ITP in the U.S. and had a limited development pipeline [5].